Search Follow us

RedHill Biopharma (RDHL)

Business description

RedHill Biopharma is a specialty pharma company with a broad R&D pipeline focusing on gastrointestinal and inflammatory diseases and also promotes four GI products in the US. The most advanced programs are TALICIA (RHB-105) for H. pylori infection, RHB-104 for Crohn’s disease, BEKINDA for gastroenteritis and IBS-D, and RHB-204 for NTM.

Stock data

Market cap.US$140.1m
Last closeUS$8.21
High / Low (52 weeks)US$11.3 / US$4.6
Stock market listingUS, Tel Aviv Stock Exchange
Forecast net cash (US$m)24.7
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual4.5(27.3)(7.2)
Relative *7.4(27.3)(15.5)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
ADL Bionatur Solutions Adocia
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Antibe Therapeutics Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Arix Bioscience Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
ASIT Biotech ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Auris Medical
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Avivagen Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLargo BioLight Life Sciences
BioLineRx BiondVax Pharmaceuticals
Bionomics Bionor Pharma
BioPorto Diagnostics Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
Bonesupport BrainStorm Cell Therapeutics
Brighter BTG
C4X Discovery Holdings Caladrius Biosciences
Can-Fite BioPharma CannTrust Holdings
Cantargia Capstone Therapeutics
Carmat CASI Pharmaceuticals
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Deinove Delcath Systems
Deltex Medical Derma Sciences
Destiny Pharma DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Technologies Ellex Medical Lasers
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Herantis Pharma Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Immutep
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
InMed Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
Japan Tobacco KaloBios Pharmaceuticals
Kane Biotech Karolinska Development
Kazia Therapeutics Keryx Biopharmaceuticals
Kiadis Pharma Laboratorios Farmacéuticos ROVI
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medicure Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncology Venture
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics OSE Immunotherapeutics
Ossur OvaScience
OWL Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Pluristem Therapeutics Prescient Therapeutics
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
Race Oncology Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Sierra Oncology Silence Therapeutics
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals T‐cell cancer therapies
Targovax TearLab Corp
Tekmira Telix Pharmaceuticals
TESARO Theraclion
Therapix Biosciences Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

RedHill Biopharma Ltd. ADR

Sun, 27 Mar 2016 01:50:36 GMT

Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year ...

Mon, 05 Jun 2017 19:56:44 GMT

Valeant Pharmaceuticals Intl Inc (VRX) Keeps Fighting to Turnaround Debt ...

Tue, 03 Oct 2017 18:48:38 GMT

RedHill Biopharma reports positive results from mid-stage trial of irritable ...

Tue, 03 Oct 2017 11:03:45 GMT

IntelGenx Technologies Corp. (OTCMKTS:IGXT) and RedHill Biopharma Ltd – ADR ...

Thu, 02 Oct 2014 13:24:07 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2016A 0.1 (30.5) (29.4) (22.85) N/A N/A
2017A 4.0 (51.9) (45.5) (25.99) N/A N/A
2018E 12.4 (39.1) (39.2) (16.72) N/A N/A
2019E 30.2 (36.6) (36.7) (14.36) N/A N/A

Last updated on 02/10/2018

Latest research

המחקר העדכני ביותר

רדהיל ביופארמה

RedHill Biopharma:לפני סוף השנה TALICIA עם IIIתוצאות מניסוישלב

02/10/2018
רדהיל ביופארמה

RedHill Biopharma: םיניוצמ םיארנ RHB-104 ינותנ

08/08/2018
רדהיל ביופארמה

RedHill Biopharma: ,)GI( לוכיעה יכרד ירצומ לש תוריכמ תחימצ ךשמה םישדח 3 -כ דועב ןהורקב III בלש יוסינ תואצות

24/05/2018
רדהיל ביופארמה

מו"פ הממוקד בתרופות גסטרו מגיע לשלב המסחרי

29/03/2018
רדהיל ביופארמה

IBS-D- ל BEKINDA ניסוי שלב 2 מוצלח עם

27/11/2017
רדהיל ביופארמה

RedHill Biopharma- חברת תרופות בעלת זרזים פיננסיים עתידיים רבים

24/11/2016

Investment summary

In the past few weeks, RedHill has reached several R&D milestones: completion of enrolment for the Phase III TALICIA study for H. pylori infection (data end-2018), advancement to the second stage of the Phase IIa YELIVA study for cholangiocarcinoma, and a positive FDA meeting to discuss BEKINDA for IBS-D (now Phase III-ready). In addition, on 14 August RedHill announced a successful equity raise of $25m gross ($23.5m net), which will be used to fund the company’s ongoing R&D programmes. Our valuation is slightly higher at $432m (NIS1.5bn) but lower on a per share basis $16.9/ADS (NIS6.1/share) after the share issue.

Last updated on 02/10/2018

Industry outlook

RedHill's main focus on GI and inflammation include a range of conditions, which although can be treated with a variety of innovative and established products, there is still an unmet need in each of the diseases. In our view, carefully positioned, innovative solutions for the patients will attract attention.

Last updated on 28/09/2018

Key management

Dror Ben-Asher, CEO
Micha Ben-Chorin, CFO
Gilead Raday, Chief Operating Officer
Shani Maurice, VP Business Development & Communications
Adi Frish, Senior VP Business Development & Licencing
Alexandra Okmian, Business Development and Investor Relations M
Guy Goldberg, Chief Commercial Officer

Company address

21 Ha’arba’a St.
Tel-Aviv
6473921
Israel
+972-(0)3-541-3131
View website